Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Network interactions in schizophrenia - therapeutic implications.

A Carlsson1, N Waters, S Waters

  • 1Department of Pharmacology, University of Göteborg, Box 431, SE 40530, Göteborg, Sweden. Arvid.Carlsson@pharm.gu.se

Brain Research. Brain Research Reviews
|March 17, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cluster, facets, and edges: site-dependent selective chemistry on model catalysts.

Chemical record (New York, N.Y.)·2003
Same author

Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis.

Current drug targets. CNS and neurological disorders·2003
Same author

Noonan's syndrome and autoimmune diseases.

Journal of pediatric endocrinology & metabolism : JPEM·2003
Same author

Identification of a susceptibility locus for migraine with and without aura on 6p12.2-p21.1.

Neurology·2002
Same author

A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture.

Bioscience reports·2002
Same author

Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems.

Journal of neural transmission (Vienna, Austria : 1996)·2002

Recent research highlights dopamine dysfunction in schizophrenia pathogenesis, supported by advanced imaging and new pharmacological tools. Network stabilization emerges as a promising therapeutic strategy, with clinical trials underway for novel treatments.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia pathogenesis research has advanced significantly.
  • Dopamine dysfunction hypothesis now has direct evidence from sophisticated imaging techniques.
  • Complex interactions between neurotransmitters in neural networks are increasingly understood.

Purpose of the Study:

  • To summarize recent advances in understanding schizophrenia pathogenesis.
  • To highlight the role of neurotransmitters and neural networks.
  • To discuss emerging therapeutic strategies and clinical trials.

Main Methods:

  • Sophisticated neuroimaging techniques provided direct evidence for dopamine dysfunction.
  • Development of novel pharmacological probes revealed neurotransmitter interactions.

Related Experiment Videos

  • Clinical trials are evaluating new therapeutic agents.

    • Main Results:

    • Direct support for the dopamine dysfunction hypothesis in schizophrenia.
    • Identification of interactions between dopamine and other neurotransmitters in neural networks.
    • Pharmacological models of schizophrenia (hyperdopaminergia, hypoglutamatergia) are ready for testing.

    Conclusions:

    • Network stabilization is a validated therapeutic strategy.
    • Ongoing clinical trials targeting dopaminergic, serotonergic, and glutamatergic receptors offer therapeutic optimism.
    • Advances in understanding neurotransmitter roles provide a foundation for new schizophrenia treatments.